ClinicalTrials.gg
RecruitingNCT06574269Updated Dec 2, 2025

A Study on TLC590 for Managing Postsurgical Pain

A Phase 2 interventional study of TLC590 and TLC590 in Postsurgical Pain Management, sponsored by TLC Biopharmaceuticals, Inc.. Recruiting at 2 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-12-02.

Sponsored by TLC Biopharmaceuticals, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Sep 2024; still recruiting 2 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 184 studies testing ropivacaine in Pain, Postoperative — 20 open to participants now, 22 under way, 2 of them phase 3. Ropivacaine · Pain, Postoperative.

Planned enrollment
30th of 184
120 · median 70
Started
2024
with 5 others
Phase 2
10 of 184
3 open now
Primary completion
2026-07
later than 10 of 21 live
Registered
175th of 184
by date

Among the 184 studies testing ropivacaine in Pain, Postoperative, this one is the 30th largest by planned enrollment, is one of 6 that started in 2024, is one of 10 in phase 2, reaches primary completion later than 10 of the 21 other live ones, and was the 175th registered.

Pain, Postoperative

5,654 studies on the registry are indexed under Pain, Postoperative; 1,233 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

20 of the 184 studies testing ropivacaine in Pain, Postoperative are open now, in 10 countries. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 20 open studies →

About ropivacaine

Ropivacaine: first FDA approval 1996 (NAROPIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 676 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 327 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 184 studies testing ropivacaine in Pain, Postoperative, or all of them as a file.
02

Study summary

This Phase 2 open-label trial investigates the pharmacokinetics (PK), pharmacodynamics, and safety profile of TLC590 across various surgical procedures. Researchers aim to determine the maximum tolerated dose (MTD) of TLC590 via Safety Monitoring Committee (SMC).

The study evaluates TLC590 in bunionectomy, laparoscopy-assisted open ventral hernia repair, breast augmentation, abdominoplasty, and total knee arthroplasty models. Additionally, it determines the relative bioavailability of TLC590 to ropivacaine injection.

Read the detailed description

This Phase 2, open-label, multi-center study is a 3-part study to be performed in approximately 120 subjects undergoing multiple surgical procedures receiving TLC590 or ropivacaine injection. Subjects eligible based on inclusion and exclusion criteria will receive study drug administered via infiltration. Subjects entering all parts of the study will undergo the consent and screening procedures, eligibility requirements, and PK and safety evaluations during their participation in the study.

03

Conditions studied

  • Postsurgical Pain Management

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able and willing to provide written
  2. Male or female aged 18 to 70 years, inclusive. For the Part 2 breast augmentation surgical model, only females can be enrolled
  3. Scheduled to undergo one of the following elective surgeries, with no additional procedures and be able to use the anesthesia regimen:

    1. Unilateral first metatarsal bunionectomy (Cohort 1)
    2. Laparoscopy-assisted open ventral hernia repair (Cohort 2 and 6)
    3. Breast augmentation (Cohort 3 through 5)
    4. Unilateral total knee arthroplasty (Cohort 7)
    5. Abdominoplasty (tummy tuck) (Cohort 8)
  4. ASA Physical Status Classification of 1 or 2
  5. Male subjects must be either biologically or surgically sterile or commit to the use of a reliable method of (must agree to use double-barrier contraception in the event of sexual activity) or be practicing abstinence for the duration of the study and for 30 days after study drug administration
  6. Female subjects are eligible only if all the following apply:

    1. Not pregnant with a negative serum pregnancy test at Screening and negative urine pregnancy test on Day 1 before surgery (pregnancy test not required for females of non-, defined as surgically sterile or )
    2. Not lactating
    3. Not planning to become pregnant during the study
    4. If of childbearing potential, commits to the use of a highly effective method of birth control for the duration of the study and or at least 30 days after study drug administration
  7. >18 \~ ≤39 kg/m2

Exclusion criteria

Exclusion Criteria:

  1. A abnormal clinical laboratory test value
  2. Evidence of a clinically significant 12-lead
  3. History of orthostatic hypotension, syncope, or other syncopal attacks
  4. History or any clinical manifestation of significant renal, hepatic, gastrointestinal, cardiovascular, metabolic, neurologic, psychiatric, or other condition that has been assessed by the Investigator to be unsuitable for participation in the study
  5. History of seizures or taking anticonvulsants during the Screening period
  6. History of cardiac arrhythmia or taking Class III antiarrhythmic drugs including amiodarone, dofetilide, dronedarone, sotalol, or ibutilide during the Screening period
  7. History of sleep apnea or on home CPAP treatment
  8. History of to ropivacaine, any other amide-type local anesthetic, propofol, hydromorphone, fentanyl, midazolam, acetaminophen, oxycodone, or morphine (or other opioids)
  9. History of severe or PONV due to other etiologies, including, but not limited to gastric outlet obstruction, hypercalcemia, or active peptic ulcer, deemed clinically significant by the Investigator
  10. Any lifetime history of a suicidal attempt or any suicidal behavior, as assessed by the C-SSRS at Screening
  11. History or positive test results of , , or
  12. History or current report of substance abuse including illicit drug abuse and/or alcohol abuse (regularly drinks >4 units of alcohol per day: 1 unit = 8 oz. beer, 3 oz. wine, or 1 oz. spirits) within 2 years prior to Screening
  13. Positive results on the urine drug screen or alcohol breath test indicative of illicit drug or non-prescribed drug or alcohol abuse at Screening or on Day 1 before surgery. Prescribed medication that is known to result in a positive drug test is allowed. Marijuana (medical or recreational) is not allowed
  14. Pre-existing concurrent acute, or chronic painful restrictive/physical condition that may confound postoperative pain assessments or is expected to require analgesic treatment during the study
  15. Has known or suspected daily use of opioids for longer than 4 days per week within the previous 6 months prior to Screening
  16. Is taking daily analgesics for longer than 4 days per week for a chronically painful condition during the Screening period. Not exclusionary if it is utilized for pain related to the total knee arthroplasty indication
  17. Is receiving oxygen therapy during the Screening period
  18. Use of any of the following medications within 5 half-lives prior to the study surgical procedure or as specified
  19. in the last 2 years prior to Screening, except for non- basal cell or squamous cell carcinoma of the skin or localized carcinoma in situ of the cervix
  20. Personal or family history of malignant hyperthermia
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Part 1, Cohort 1

    Bunionectomy: Increasing dose cohorts for TLC590

    Drug: TLC590

  • Experimental
    Part 1, Cohort 2

    Laparoscopy-assisted Open Ventral Hernia: TLC590

    Drug: TLC590

  • Experimental
    Part 2, Cohort 3

    Breast Augmentation: TLC590 or Ropivacaine

    Drug: TLC590 · Drug: Ropivacaine

  • Experimental
    Part 2, Cohort 4

    Breast Augmentation: TLC590 or Ropivacaine

    Drug: TLC590 · Drug: Ropivacaine

  • Experimental
    Part 2, Cohort 5

    Breast Augmentation: TLC590 with the SMC-suggested dose

    Drug: TLC590

  • Experimental
    Part 3, Cohort 6

    Laparoscopy-assisted Open Ventral Hernia: The MTD of TLC590

    Drug: TLC590

  • Experimental
    Part 3, Cohort 7

    Total Knee Arthroplasty: The MTD of TLC590

    Drug: TLC590

  • Experimental
    Part 3, Cohort 8

    Abdominoplasty: The MTD of TLC590

    Drug: TLC590

Interventions

  • DrugTLC590

    Sequentially enrolled into increasing dose cohorts from low to high to receive a dose of TLC590

    Also known as: TLC590 (Ropivacaine Extended-Release Injectable Suspension)

  • DrugTLC590

    TLC590 Dose 1

    Also known as: TLC590 (Ropivacaine Extended-Release Injectable Suspension)

  • DrugTLC590

    TLC590 Dose 2

    Also known as: TLC590 (Ropivacaine Extended-Release Injectable Suspension)

  • DrugTLC590

    The MTD of TLC590

    Also known as: TLC590 (Ropivacaine Extended-Release Injectable Suspension)

  • DrugTLC590

    TLC590 Dose 3 (The SMC-suggested dose)

    Also known as: TLC590 (Ropivacaine Extended-Release Injectable Suspension)

  • Ropivacaine

    Also known as: Ropivacaine HCL Injection

  • DrugTLC590

    TLC590

    Also known as: TLC590 (Ropivacaine Extended-Release Injectable Suspension)

06

What researchers measure

Primary outcomes

  1. To determine the relative bioavailability of TLC590 compared to ropivacaine HCl injection (Part 2)

    Time frame: 0-168 hours

  2. To determine the MTD of TLC590 in subjects with breast augmentation surgery (Part 2)

    Time frame: 30 days

07

Study locations

2 of 2 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Jul 2026, 22 months after the start.

Of 49 industry-sponsored phase 2 interventional studies under Pain, Postoperative, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 11. This study's planned 22 months is above that.

Counting every sponsor, half of 139 studies reached it within 12 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2024
First posted
Aug 27, 2024
StartActual
Sep 30, 2024
Primary completionEst.
Jul 2026
CompletionEst.
Aug 2026
Last update
Dec 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06574269
Lead sponsor
TLC Biopharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Aug 27, 2024
Start date
Sep 30, 2024
Primary completion
Jul 2026 (estimated)
Completion
Aug 2026 (estimated)
Last update
Dec 2, 2025

Study contacts

Jack Chang
Contact
Jack@tlcbio.com
+886-2-26557377
Tien-Tzu Tai, MD
study director · Taiwan Liposome Company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ropivacaine

Start the discussion